Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• EGFR Exon20 insertions are a rare but aggressive subset of non-small cell lung cancer (NSCLC).
• Existing therapies often exhibit limited efficacy and significant toxicity against these mutations.

Purpose of the Study:

• To identify and optimize novel inhibitors targeting EGFR Exon20 insertions.
• To achieve high selectivity over wild-type EGFR to minimize off-target effects and toxicity.

Main Methods:

• High-throughput screening (HTS) campaign.
• Structure-based drug design (SBDD) with iterative optimization.
• Linker modification strategies.

Main Results:

• Discovery of a potent series of wild-type selective EGFR Exon20 insertion inhibitors.
• Compound 36 demonstrated potent and selective inhibition of EGFR Exon20 insertions.
• Compound 36 showed encouraging efficacy in NSCLC xenografts with SVD Exon20 insertion.
• Compound 36 exhibited reduced efficacy in wild-type EGFR xenografts compared to CLN-081, suggesting lower wild-type associated toxicity.

Conclusions:

• Compound 36 represents a promising therapeutic candidate for NSCLC patients with EGFR Exon20 insertions.
• The developed inhibitors display a favorable selectivity profile, potentially leading to improved safety and tolerability.